Cited by 871Sepsis Diagnosis and TreatmentAutoimmune and Inflammatory Disorders ResearchInflammation biomarkers and pathways

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Open access

Shakoory, Bita, Carcillo, Joseph A., Chatham, W. Winn, Amdur, Richard L., Zhao, Huaqing, Dinarello, Charles A., Cron, Randall Q., Opal, Steven M.·2016·Critical Care Medicine

DOI 10.1097/ccm.0000000000001402PMC PMC5378312

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ccm.0000000000001402

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citation
The Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citation
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citation
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citation
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citation
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637

Show all 48 references

Research works printed but not linked: 4

Emmenegger, 2005, Swiss Med Wkly, 135, 299
Behrens, 2007, J Rheumatol, 34, 1133
Behrens, 2006, J Rheumatol, 33, 2081
Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388

Sorted by citations

Items 601–700 of 871

Macrophage Activation Syndrome
Iosim, S., & Henderson, L. A. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.02.004 · Cited by 5
IL-1 Superfamily and Inflammasome
Dinarello, C. A. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch20 · Cited by 5
Self-citation
Therapeutic options for the management of severe COVID-19: A rheumatology perspective
Pinto, C. M., García‐Carrasco, M., Munguía‐Realpozo, P., & Méndez‐Martínez, S. (2020) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2020.05.002 · Cited by 5
Epstein-Barr virus associated haemophagocytic lymphohistiocytosis treated with anakinra and rituximab: A case report
McCann, N. S., Amarnani, R., Shipa, M. R. A., Ahmed, S., Mohideen, F. T., Vöö, S. A., & Manson, J. J. (2020) · Clinical Infection in Practice · doi:10.1016/j.clinpr.2020.100060 · Cited by 5
Inflammatory pathways and potential therapies for COVID-19: A mini review
Dabbish, A. M., Yonis, N., Salama, M., Essa, M. M., & Qoronfleh, M. W. (2021) · European Journal of Inflammation · doi:10.1177/20587392211002986 · Cited by 5
Dietary Fiber Drives IL-1β–Dependent Peritonitis Induced by Bacteroides fragilis via Activation of the NLRP3 Inflammasome
Jennings-Almeida, B., Castelpoggi, J. P., Ramos‐Junior, E. S., Ferreira, E. D. O., Domingues, R. M. C. P., Echevarria‐Lima, J., Coutinho‐Silva, R., Moreira-Souza, A. C. A., Mariño, E., Mackay, C. R., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000078 · Cited by 5
Case Report: Immune Dysregulation Due to Toxoplasma gondii Reactivation After Allogeneic Hematopoietic Cell Transplant
Lindell, R. B., Wolf, M. S., Alcamo, A. M., Silverman, M. A., Dulek, D. E., Otto, W. R., Olson, T. S., Kitko, C. L., Paueksakon, P., & Chiotos, K. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.719679 · Cited by 5
IL-1 Family Blockade in Cytokine Storm Syndromes
Cron, R. Q. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_31 · Cited by 5
Self-citation
COVID‐19 and new‐onset arrhythmia
Singh, S., & Desai, R. (2020) · Journal of Arrhythmia · doi:10.1002/joa3.12354 · Cited by 5
Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review
Andaluz‐Ojeda, D., Vidal, P., Sanz, Á. A., Suberviola, B., Carbajo, L. D. R., Martín, L. N., Silva, E. P., Olmo, J. N.-D., Barberán, J., & Cusácovich, I. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i4.269 · Cited by 6
Hemophagocytic lymphohistiocytosis: an update in diagnostics, criteria, and treatment considerations
Coffey, K. E., & Minnicozzi, S. C. (2025) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001508 · Cited by 4
Platelets in Neonatal Sepsis: Beyond Clotting, from Silent Players to Immune Orchestrators
Sokou, R., Lianou, A., Tsantes, A. G., Petrou, E., Bonovas, S., Nikolopoulos, G. K., Tsantes, A. Ε., & Iacovidou, N. M. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2731-2399 · Cited by 4
Differential protein expression and enriched pathways in pediatric sepsis: identification of novel brain-associated biomarkers revealed through proteomic profiling
Stranges, V., Tweddell, D., Cela, E., Morello, M., Daley, M., Cepinskas, G., & Fraser, D. D. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01397-x · Cited by 5
YOD1 promotes ferroptosis in acute lung injury by deubiquitination of NCOA4
Yan, X., Chen, Y., Li, X., Chang, Q., Li, X., Chen, Y., Huang, C., Ruan, T., Xu, G., Chen, C., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09237-8 · Cited by 4
Bloodstream Infection-induced Neuroinflammation: from Systemic Infection To Brain Invasion
Anand, G., & Lahariya, R. (2025) · Current Microbiology · doi:10.1007/s00284-025-04626-y · Cited by 5
Immune Endotype-Guided Precision Immunotherapy in Sepsis: From Transcriptomics to Bedside Application
Badero, O. J., Omokore, O. A., Oore-ofe, O., Osibowale, B. T., Quadri, I. O., Olayinka, T. O., Olabode, D., Kalu, K. E., Adeyemi, A., Buari, M. O., et al. (2026) · Cureus · doi:10.7759/cureus.106312 · Cited by 5
Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies
Xu, X., Chen, J., Feng, Y., Zou, C., Peng, X., Wang, Z., Ma, Y. X., Xie, Y., Li, H., & Zhang, D. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02782-6 · Cited by 5
Characteristics and Risk Factors for Pediatric Sepsis
Zhu, Y., Liu, T.-L., Dai, Q., Liu, S.-F., Xiong, P., Huang, H., Yuan, Y., Zhang, T., & Chen, Y. (2024) · Current Medical Science · doi:10.1007/s11596-024-2870-6 · Cited by 4
IL-1beta expressing neutrophil extracellular traps in Legionella pneumophila infection
Koutantou, M., Konstantinidis, T. G., Chochlakis, D., Xingi, E., Psaroulaki, A., Tsiotis, G., Kambas, K., & Angelakis, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573151 · Cited by 5
Management of Patients with Connective Tissue Disease-associated Interstitial Lung Diseases During the COVID-19 Pandemic
Gurkan, C. G., Karadoğan, D., Ufuk, F., Cüre, O., & Altınışık, G. (2021) · Turkish Thoracic Journal · doi:10.5152/turkthoracj.2021.20172 · Cited by 4
Therapeutic targeting of inflammasome signaling by blocking interleukin-1
Coll, R. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00010-4 · Cited by 3
Systems-wide view of host-pathogen interactions across COVID-19 severities using integrated omics analysis
Singh, M. S., Pyati, A., Rubi, R. D., Subramanian, R., Muley, V. Y., Ansari, M. A., & Yellaboina, S. (2024) · iScience · doi:10.1016/j.isci.2024.109087 · Cited by 4
Inhibition of PI3K p110δ rebalanced Th17/Treg and reduced macrophages pyroptosis in LPS-induced sepsis
Zhang, S., Shan, J., Jie, Y., Zhang, X., Zhu, M., Shen, J., Mao, K., Chen, W., Wang, Y., & Wen, Y. (2024) · Molecular Immunology · doi:10.1016/j.molimm.2024.04.008 · Cited by 4
The Novel Role of the Expression of Toll-like Receptors TLR-5, TLR-6, and TLR-9 and Associated Up-Regulation of Programmed Cell Death 1 Receptor (PD-1) and Its Ligand (PD-L1) in Lung Sepsis
Sinos, G., Schizas, D., Kapelouzou, A., Frountzas, M., Katsimpoulas, M., Mylonas, K. S., Kapetanakis, E. I., Papalampros, A., Liakakos, T., & Alexandrou, A. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052274 · Cited by 4
Analysis of the COVID-19 epidemic: an additional narrative; an alternative response
Rennebohm, R. (2020) · Pediatrician (St Petersburg) · doi:10.17816/ped11323-40 · Cited by 4
Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation
Rosée, P. G. L., Bremer, H., Rosée, F. L., Mohm, P., Hochhaus, A., Gehrke, I., Kumle, B., Benzing, A., & Russo, S. G. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00750-8 · Cited by 4
Recomendaciones para la sospecha diagnóstica y manejo del Síndrome Inflamatorio Multisistémico (SIM-COVID-19) en contexto pandemia SARS-CoV-2. Abril 2021
Giannina Izquierdo, C., Fernanda Cofré, S., Poli, M. C., Delpiano, L., Conca, N., Verdugo, P., Álvarez, P., Acevedo, V. S., & Tapia, L. I. (2021) · Revista chilena de infectología · doi:10.4067/s0716-10182021000300370 · Cited by 4
Murine typhus complicated by sHLH mimicking adult-onset Still's disease
Jacquot, R., Gerfaud‐Valentin, M., Lega, J., Becker, A., Jamilloux, Y., & Sève, P. (2022) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2022.05.011 · Cited by 4
Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review
Hays, L. M. C., Black, M., Prunty, M. P., Murthy, S., van de Veerdonk, F. L., Annane, D., Binnie, A., Burrell, A. J. C., Derde, L. P. G., Gordon, A. C., et al. (2022) · HRB Open Research · doi:10.12688/hrbopenres.13613.1 · Cited by 4
Protein-mediated interactions in the dynamic regulation of acute inflammation
Stark, R. J. (2023) · Biocell · doi:10.32604/biocell.2023.027838 · Cited by 4
Acute cerebrovascular events and inflammatory markers associated with COVID-19: An observational study
Abdelazim, I. A., Jumagaliyeva, M. B., Ayaganov, D. N., Saparbayev, S. S., Tuychibaeva, N. M., & Kurmambayev, Y. (2023) · Journal of Medicine and Life · doi:10.25122/jml-2023-0283 · Cited by 4
Bacteria-Associated Cytokine Storm Syndrome
Eloseily, E. M., & Cron, R. Q. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_19 · Cited by 4
Self-citation
Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements
Tuli, H. S., Sood, S., Kaur, J., Kumar, P., Seth, P., Punia, S., Yadav, P., Sharma, A. K., Aggarwal, D., & Sak, K. (2021) · 3 Biotech · doi:10.1007/s13205-021-02644-8 · Cited by 4
Is Interleukin-1 Receptor Blockade Ready for Prime Time in Patients With Severe Sepsis and Macrophage Activation Syndrome?*
Johnson, D. W., & Kalil, A. C. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001460 · Cited by 4
Nitrite Attenuates the In Vitro Inflammatory Response of Immune Cells to the SARS-CoV-2 S Protein without Interfering in the Antioxidant Enzyme Activation
Ferrer, M. D., Reynés, C., Jiménez, L., Malagraba, G., Monserrat-Mesquida, M., Bouzas, C., Sureda, A., Tur, J. A., & Pons, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053001 · Cited by 3
Current status of immunomodulatory therapies in adult sepsis patients: where do we stand?
Papatheodosiou, D., Giamarellos‐Bourboulis, E. J., & Tsoukas, C. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2646192 · Cited by 3
Exploring the mechanisms and management of sepsis-related cardiac dysfunction
Iqbal, M. S., Khan, M. F., Farooqui, S., Iqbal, M. Z., Khan, S.-U.-D., & El‐Sehrawy, A. A. M. A. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2664100 · Cited by 3
Macrophage metabolic reprogramming in sepsis-associated acute lung injury: mechanisms and therapeutic strategies
Pan, R., Sun, Y., Chen, L., 潘建平, & Guo, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1808474 · Cited by 3
The dual balance of the cytokine network: key messengers of immune activation and triggers of cytokine storm
Zhang, Y., Guo, D., Zhou, Y., Wang, C., Su, G., Huang, J., Wan, Y., Zhang, H., Wan, H., Bo, L., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00948-6 · Cited by 4
Host-directed immune therapies: a second front in the battle against sepsis
Hotchkiss, R. S., & Monneret, G. (2026) · Journal of Clinical Investigation · doi:10.1172/jci204736 · Cited by 3
Médicaments rhumatologiques pour le traitement de l’infection par le COVID-19
Benucci, M., Damiani, A., Infantino, M. G., Manfredi, M., & Quartuccio, L. (2020) · Revue du Rhumatisme · doi:10.1016/j.rhum.2020.03.010 · Cited by 3
Specific and Non-specific Aspects and Future Challenges of ICU Care Among COVID-19 Patients with Obesity: A Narrative Review
Beurton, A., Kooistra, E. J., JONG, A. D., Schiffl, H., Jourdain, M., Garcia, B., Vimpère, D., Jaber, S., Pickkers, P., & Papazian, L. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00562-3 · Cited by 3
Two dramatically different clinical scenarios of neonatal Echovirus-11 infection in late preterm male twins: a case report and review of the literature
Perniciaro, S., Proietti, C., Bossi, A., Maragliano, R., Facco, C., Novazzi, F., Mancini, N., & Agosti, M. A. (2025) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-025-01880-5 · Cited by 3
HLH in Adults
Rosée, P. G. L., & Machowicz, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-59632-7_16 · Cited by 3
Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome
Steinhardt, M., Wiebecke, S., Weismann, D., Frantz, S., Tony, H., Klinker, H., & Schmalzing, M. (2020) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2020.1789734 · Cited by 3
Síndrome inflamatorio multisistémico en niños con COVID-19: una visión desde la reumatología
Arango, Y. A. N., Cortés, A. Y. A. A. F., Henao, J. P. G., Slingsby, C. V. A., & Rivera, L. M. S. (2020) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2020.09.005 · Cited by 3
COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS
Жукова, О. В., Kagramanyan, I. N., & Хохлов, А. Л. (2021) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2020-8-5-316-324 · Cited by 3
The impact of the COVID-19 pandemic on the field of pediatric rheumatology
Wahezi, D. M., Peskin, M., & Tanner, T. (2021) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000814 · Cited by 3
Fatal Pediatric Melioidosis and the Role of Hyperferritinemic Sepsis-Induced Multiple-Organ Dysfunction Syndrome
Mohan, A., Paranchothy, M., Segaran, S., Wong, R. S.-C., Chor, Y. K., Podin, Y., & Ooi, M.-H. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0051 · Cited by 3
Waterhouse-Friderichsen syndrome following a dog bite in an asplenic patient: case report and review of the literature
Berlot, G., Tomasini, A., Zanchi, S., Moro, E., Pinamonti, M., Mohamed, S., & Bellis, E. D. (2023) · International Journal of Emergency Medicine · doi:10.1186/s12245-023-00483-3 · Cited by 3
Hemophagocytic Lymphohistiocytosis
Lachmann, G., & Brunkhorst, F. M. (2023) · Lessons from the ICU · doi:10.1007/978-3-031-17572-5_4 · Cited by 3
The Bisdioxopiperazine ICRF-193 Attenuates LPS-induced IL-1β Secretion by Macrophages
Brindle, A., Bainbridge, C., Kumar, M. R., Todryk, S. M., & Padget, K. (2023) · Inflammation · doi:10.1007/s10753-023-01895-2 · Cited by 3
Natural products for treating cytokine storm-related diseases: Therapeutic effects and mechanisms.
Liu, M., Wang, Q., Xu, W., Wu, J., Xu, X., Yang, H., & Li, X. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115555 · Cited by 3
Effect of anakinra in COVID-19
Kooistra, E. J., Waalders, N. J. B., Kox, M., & Pickkers, P. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30235-6 · Cited by 3
Opciones terapéuticas en el manejo de la COVID-19 grave: una perspectiva de Reumatología
Pinto, C. M., García‐Carrasco, M., Munguía‐Realpozo, P., & Méndez‐Martínez, S. (2020) · Reumatología Clínica · doi:10.1016/j.reuma.2020.05.002 · Cited by 3
Comprehensive review on novel COVID-19: a Saudi perspective
Alkhowailed, M. S., Alqossayir, F., Rasheed, Z., Alkhamiss, A. S., Alsalloom, A. A., Ali, A. S., Shariq, A., Alamer, A., Almohaileb, F. I., Alharb, M. H., et al. (2020) · Arab Journal of Basic and Applied Sciences · doi:10.1080/25765299.2020.1852731 · Cited by 3
Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists
Janda, A., Schuetz, C., Canna, S., Gorelik, M., Heeg, M., Minden, K., Hinze, C. H., Schulz, A., Debatin, K., Hedrich, C. M., et al. (2021) · Rheumatology International · doi:10.1007/s00296-021-04824-4 · Cited by 3
A role for interleukin-1 receptor antagonism in severe COVID-19?
Tattersall, R. S., McGonagle, D., & Manson, J. J. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00249-6 · Cited by 3
T-cell Co-inhibitory Molecules in Sepsis-induced Immunosuppression
Xie, J., Qiu, H.-B., & Yang, Y. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.205867 · Cited by 3
Biological Modifiers of Inflammatory Diseases
Chatham, W. (2019) · Clinical Immunology · doi:10.1016/b978-0-7020-6896-6.00089-2 · Cited by 2
Self-citation
Hämophagozytische Lymphohistiozytose bei unspezifischer Virusinfektion
Lachmann, G., Knaak, C., Rosée, P. G. L., Spies, C., Nyvlt, P., Oberender, C., Sander, L. E., Suttorp, N., & Müller-Redetzky, H. (2019) · Der Anaesthesist · doi:10.1007/s00101-019-00634-3 · Cited by 3
IL-1 family cytokines in chronic inflammatory disorders
Střı́ž, I. (2019) · Vnitřní lékařství · doi:10.36290/vnl.2019.020 · Cited by 3
Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options
Alrahmany, D., & Ghazi, I. M. (2020) · Reviews in Medical Microbiology · doi:10.1097/mrm.0000000000000242 · Cited by 3
COVID-19 and Rheumatology: so far, so close
Belov, B. S., Muravyevа, N. V., & Тарасова, Г. М. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-8-135-143 · Cited by 3
Imunologia da Doença por Coronavírus-19 (COVID-19): Uma Perspetiva Para o Clínico, nos Primeiros 4 Meses da Emergência do SARS-CoV-2
Delgado, L., Boechat, J. L., & Chora, I. (2021) · Medicina Interna · doi:10.24950/rspmi/covid19/fmup/s/2020 · Cited by 3
Lines of Treatment of COVID-19 Infection
ElGoly, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90595-4.00002-9 · Cited by 3
Novel coronavirus infection: from pathogenesis to therapy
Владиславович, Е. М., Popova, M. D., Алексеева, И. А., Pokrovsky, N. S., & Палеев, Ф. Н. (2021) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin20211601110 · Cited by 3
Biologic Response Modifiers
Bridges, J. M., & Chatham, W. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00086-1 · Cited by 3
Self-citation
Immunomodulators Acting on COVID-19: Actual Knowledge and PerspectivesPreprint
Durán, N., & Fávaro, W. J. (2020) · Preprints.org · doi:10.20944/preprints202007.0090.v1 · Cited by 3
Management dilemma in choosing evolving treatments in neutropenic septic shock
Humes, H. D., Luckritz, K. E., Gorga, S. M., Plomaritas, K., Hoatlin, S., Humes, M., & Yessayan, L. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-06798-y · Cited by 2
Dexamethasone chronotherapy of COVID-19 patients admitted to intensive care unit: an exploratory study
Abusamak, M., Hssain, A. A., Chinta, V. R., Al‐Waeli, H., Yassine, H. M., & Tamimi, F. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11322-6 · Cited by 2
Macrophage Activation-Like Syndrome in critically ill patients with sepsis: high risk patients with high mortality
Schuster, F. S., von Haefen, C., Ihlow, J., Mittermaier, M., Spies, C., Nyvlt, P., Heeren, P., Schenk, T., Janka, G., Brunkhorst, F. M., et al. (2025) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2025.101678 · Cited by 2
Serum H‐Ferritin‐To‐Ferritin Ratio as a Biomarker of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients With Hyperferritinemia
Debaugnies, F., Goetzinger, F., Wolff, F., Impens, F., Dufour, S., Haver, D. V., Gottignies, P., Laschiazza, R., Mahadeb, B. A., Meuleman, N., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70189 · Cited by 2
Early Antibiotic Therapy in Sepsis Without Shock: A Multimethod Study of Heterogeneous Treatment Effects in ICU Patients
Zhang, P., Zuo, T., Zhu, X., Wei, J., Wang, M., Zhang, X., & Huang, Y. (2026) · Infectious Diseases and Therapy · doi:10.1007/s40121-026-01316-5 · Cited by 2
Research Progress of Sepsis Immunotherapy: A Bibliometric Analysis
Wang, Z., Li, X., & Zhang, J. (2026) · Shock · doi:10.1097/shk.0000000000002826 · Cited by 2
Clinical practice in using corticosteroids and adjunctive sepsis therapies at the bedside among European ICUs: an ESICM-endorsed survey
David, S., Léone, M., Girardis, M., Müller, M. M., Gavrilović, S., Domizi, R., Damiani, E., Martín‐Loeches, I., Ferrer, R., Chousterman, B. G., et al. (2026) · Intensive Care Medicine Experimental · doi:10.1186/s40635-026-00877-6 · Cited by 2
Host Response Diagnostics in Pneumonia.
Pickens, C. I., & Cruz, C. D. (2026) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.12.009 · Cited by 2
Current State of the Fight Against Antimicrobial Resistance: What Are the Different Strategies for Tomorrow?
Wahnou, H., Kebbaj, R. E., Demoré, B., Limami, Y., & Duval, R. E. (2026) · Antibiotics · doi:10.3390/antibiotics15060564 · Cited by 2
Covid-19 Hastalığında Anti-sitokin Tedaviler: IL-6 Reseptör İnhibitörü (Tosilizumab) ve IL-1 Reseptör Antagonisti (Anakinra)
Doğru, A. (2021) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.897658 · Cited by 2
The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19
Abdelsattar, A. S., El-Awadly, Z. M., Abdelgawad, M., Mahmoud, F., Allam, S. A., & Helal, M. A. (2021) · The Open COVID Journal · doi:10.2174/2666958702101010216 · Cited by 2
Pharmacologic Treatments in Acute Respiratory Failure
Levy, E. P., & Reilly, J. P. (2023) · Critical Care Clinics · doi:10.1016/j.ccc.2023.12.002 · Cited by 2
Use of high-dose steroid therapy: addition of anakinra in the treatment of severe COVID-19
Güçlü, K. G., Geyiktepe-Güçlü, C., Bayramlar, O. F., Tunçer, G., & Aydın, M. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20230671 · Cited by 2
Clinical Phenotyping for Prognosis and Immunotherapy Guidance in Bacterial Sepsis and COVID-19
Karakike, E., Metallidis, S., Poulakou, G., Kosmidou, M. S., Gatselis, N., Petrakis, V., Rovina, N., Gkeka, E., Sympardi, S., Papanikolaou, I. C., et al. (2024) · Critical Care Explorations · doi:10.1097/cce.0000000000001153 · Cited by 2
Thrombocytopenia in Critically Ill Children: A Review for Practicing Clinicians
Totapally, B., Totapally, A., & Martinez, P. A. (2025) · Children · doi:10.3390/children12010083 · Cited by 2
TM9SF1 as a Novel Prognostic Biomarker for Sepsis Severity and Mortality: A Longitudinal Study
Wang, K., Zhang, L., Zhou, F., Zhao, Z.-W., Liu, M., Huang, M., Liu, Y., Qiu, G., Shen, X., Xiao, H. P., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s527416 · Cited by 2
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?
Rosée, P. G. L., & Machowicz, R. (2025) · Hematology · doi:10.1182/hematology.2025000707 · Cited by 2
Year 2021 in review - Intensive care
Beneš, J., Chvojka, J., Karvunidis, T., Kletečka, J., Máca, J., Zatloukal, J., & Matějovič, M. (2022) · Anesteziologie a intenzivní medicína · doi:10.36290/aim.2021.060 · Cited by 2
Cytokine Storm Syndrome Associated with Systemic Juvenile Idiopathic Arthritis
Schneider, R., Canny, S., & Mellins, E. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_21 · Cited by 2
The Role of Social Robotics to Combat COVID-19 Pandemic
Mahdy, L. N., Ezzat, K. A., Darwish, A. A., & Hassanien, A. E. (2021) · Studies in systems, decision and control · doi:10.1007/978-3-030-63307-3_13 · Cited by 2
COVID-19-associated Cytokine Release Syndrome and Autologous Conditioned Serum: A Hypothesis
Özer, K. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00006 · Cited by 2
Adult-onset Still's disease with secondary haemophagocytic lymphohistiocytosis induced acute liver failure: A case series
Gananandan, K., Thomas, R., Burke, N., Jameie‐Oskooei, S., Singh, A., Westbrook, R., & Ryan, J. D. (2021) · Journal of Liver Transplantation · doi:10.1016/j.liver.2021.100059 · Cited by 2
Idiopathic granulomatous mastitis and steroid use during the pandemic of COVID-19
Calis, H., Karabulut, Z., Guler, Y., & Sengul, S. (2022) · Breast Disease · doi:10.3233/bd-210054 · Cited by 2
Research in Pediatric Intensive Care
Prout, A., & Meert, K. L. (2022) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2022.01.015 · Cited by 2
A Comprehensive Mini-review on COVID-19 Pathogenesis on Perspectives of Cytokine Storm and Recent Developments in Anti-Covid Nucleotide Analogues
Deshmukh, R. A., & Roy, U. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.1.12 · Cited by 2
Behandlung der hämophagozytischen Lymphohistiozytose bei Patienten auf der Intensivstation
Eichenauer, D. A., & Rosée, P. G. L. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01584-0 · Cited by 2
Follow the complex bread crumbs: A review of autoinflammation for the general paediatrician
Tsoukas, P., & Laxer, R. M. (2019) · Paediatrics & Child Health · doi:10.1093/pch/pxz072 · Cited by 2
Should coronavirus disease 2019 concern rheumatologists?
Kucharz, E. J. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15366 · Cited by 2
Insights into biological therapeutic strategies for COVID-19
Tian, X., Li, C., Wu, Y., & Ying, T. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.02.001 · Cited by 2
Multisystemic inflammatory syndrome in children with COVID-19: A rheumatology perspective
Arango, Y. A. N., Cortés, A. Y. A. A. F., Henao, J. P. G., Slingsby, C. V. A., & Rivera, L. M. S. (2021) · Revista Colombiana de Reumatología (English Edition) · doi:10.1016/j.rcreue.2020.09.004 · Cited by 2
Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patientsPreprint
Lorenz, G., Moog, P., Bachmann, Q., Rosée, P. G. L., Schneider, H., Schlegl, M., Spinner, C. D., Heemann, U. W., Schmid, R. M., Algül, H., et al. (2020) · doi:10.21203/rs.3.rs-31847/v1 · Cited by 2

Authors: Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
Affiliations: George Washington University (US)
University of Pittsburgh Medical Center (US)
University of Alabama at Birmingham (US)
Temple University (US)
University of Colorado Anschutz (US)
Brown University (US)
ORCID: Shakoory, Bita
Carcillo, Joseph A.
Chatham, W. Winn
Amdur, Richard L.
Zhao, Huaqing
Dinarello, Charles A.
Venue: Critical Care Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2016-02
Volume: 44
Issue: 2
Pages: 275-281
ISSN: 0090-3493 (ISSN-L)
DOI: 10.1097/ccm.0000000000001402
PMC: PMC5378312
OpenAlex: W2177407033
Cited by: 867
References: 48
Citations by year: 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
FWCI: 24.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Critical Care Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of General Medical Sciences (R01GM108618)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords: sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
MeSH terms: Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks